Ollin Biosciences to Participate in Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences:

2026 Jefferies Global Healthcare Conference
1x1 Meetings: Tuesday, June 2
New York, NY

Evercore 2026 Emerging Private Biotech Conference
Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET
Newport, RI

About Ollin Biosciences

Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526926052/en/

Media:
Katie Engleman
1AB
[email protected]

Source: Ollin Biosciences, Inc.

You May Also Be Interested In

• NetApp Reports First Quarter of Fiscal Year 2027 Results
• Citi’s Services Business Pioneers Live Transactions on Swift’s Ledger, Collaborating with FAB and OCBC to Redefine Always-On Global Payments
• Redwood Credit Union Ranks Among Top 25 Bay Area Companies for Corporate Philanthropy